Samsung Bioepis and Epis NexLab announced a research collaboration and licence agreement with G2GBIO, a company specialising in the development of sustained-release formulations, to develop novel assets based on G2GBIO’s proprietary microsphere technology.

Under the agreement, Samsung Bioepis will be given a full licence right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO. In addition, Samsung Bioepis will be given the first negotiation rights for the three other novel assets to be determined.

Epis NexLab will be responsible for the co-development of the long-acting microsphere drug delivery platform using G2GBIO’s proprietary technology. The details of the financial terms remain confidential.

“This agreement represents an important step in expanding our drug delivery capabilities and pipeline. By leveraging G2GBIO’s proprietary microsphere technology and collaborating with Epis NexLab, we look forward to the development of innovative therapies and deliver meaningful treatment options to patients,” said Kyung-Ah Kim, President and Chief Executive Officer (CEO), Samsung Bioepis.